Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pediatric Blood and Cancer Année : 2018

Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma

Résumé

In high-risk neuroblastoma (HR-NB), the clinical significance of long-term minimal residual disease (MRD) monitoring using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for neuroblastoma mRNAs has not been investigated. We report long-term MRD follow-ups of four patients with HR-NB throughout the disease (diagnosis, remission, and relapse) and treatment course (chemotherapy, autologous and allogeneic stem cell transplantation, and donor lymphocyte and natural killer cell infusions). The results showed the stability of mRNA marker expression after different treatments and demonstrated their validity to predict relapse and assess therapeutic response. This opens up the possibility of investigating the utility of long-term molecular monitoring of MRD in prospective multicenter studies.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01926683 , version 1 (19-11-2018)

Identifiants

Citer

Andrei Tchirkov, Victoria Greze, Dominique Plantaz, Nadège Rouel, Philippe Vago, et al.. Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma. Pediatric Blood and Cancer, 2018, 65 (12), pp.e27404. ⟨10.1002/pbc.27404⟩. ⟨hal-01926683⟩
47 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More